TransEnterix, Inc. (TRXC) Short Interest Up 0.0% in March
TransEnterix, Inc. (NYSEAMERICAN:TRXC) was the target of a large increase in short interest during the month of March. As of March 29th, there was short interest totalling 38,726,892 shares, an increase of 0.0% from the March 15th total of 38,711,341 shares. Based on an average trading volume of 2,361,986 shares, the short-interest ratio is currently 16.4 days. Approximately 21.6% of the company’s shares are short sold.
Separately, Zacks Investment Research lowered shares of TransEnterix from a “buy” rating to a “hold” rating in a research note on Friday, January 11th.
In other TransEnterix news, CFO Joseph P. Slattery sold 88,871 shares of the firm’s stock in a transaction on Friday, February 22nd. The shares were sold at an average price of $3.25, for a total value of $288,830.75. Following the sale, the chief financial officer now owns 44,929 shares of the company’s stock, valued at approximately $146,019.25. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Shares of TRXC opened at $2.50 on Thursday. TransEnterix has a 1-year low of $1.65 and a 1-year high of $6.98.
TransEnterix (NYSEAMERICAN:TRXC) last announced its earnings results on Tuesday, February 26th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01). The firm had revenue of $7.50 million for the quarter, compared to analysts’ expectations of $7.35 million. The business’s revenue for the quarter was up 120.6% on a year-over-year basis.
TransEnterix, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe.
Read More: Strangles
Receive News & Ratings for TransEnterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransEnterix and related companies with MarketBeat.com's FREE daily email newsletter.